×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
PSTV – plus therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
PSTV
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/15
07:30 am
pstv
Plus Therapeutics Appoints Randy H. Goodman, PhD, MHA, as Vice President of Value Strategy & HEOR to Advance Market Access and Commercial Execution
Low
Report
Plus Therapeutics Appoints Randy H. Goodman, PhD, MHA, as Vice President of Value Strategy & HEOR to Advance Market Access and Commercial Execution
4/9
08:15 am
pstv
Plus Therapeutics (PSTV) had its price target lowered by Ascendiant Capital Markets from $475.00 to $65.00. They now have a "buy" rating on the stock.
High
Report
Plus Therapeutics (PSTV) had its price target lowered by Ascendiant Capital Markets from $475.00 to $65.00. They now have a "buy" rating on the stock.
4/9
07:30 am
pstv
Plus Therapeutics Appoints Eric J. Daniels, M.D., MBA, as Chief Development Officer to Advance Clinical Pipeline
High
Report
Plus Therapeutics Appoints Eric J. Daniels, M.D., MBA, as Chief Development Officer to Advance Clinical Pipeline
4/8
07:30 am
pstv
Plus Therapeutics Granted U.S. FDA Orphan Drug Designation to REYOBIQ™ in Pediatric Malignant Gliomas
Low
Report
Plus Therapeutics Granted U.S. FDA Orphan Drug Designation to REYOBIQ™ in Pediatric Malignant Gliomas
4/7
07:30 am
pstv
Plus Therapeutics Receives AMA PLA Code for CNSide® CSF Tumor Cell Enumeration Test, Advancing Reimbursement and U.S. Commercial Adoption
Medium
Report
Plus Therapeutics Receives AMA PLA Code for CNSide® CSF Tumor Cell Enumeration Test, Advancing Reimbursement and U.S. Commercial Adoption
4/4
01:04 am
pstv
Plus Therapeutics (PSTV) was upgraded by Wall Street Zen to "sell".
Medium
Report
Plus Therapeutics (PSTV) was upgraded by Wall Street Zen to "sell".
4/2
08:09 pm
pstv
Plus Therapeutics Secures Highmark Coverage for CNSide® CSF Assay, Expanding Reimbursement to ~75 Million Covered Lives [Yahoo! Finance]
Medium
Report
Plus Therapeutics Secures Highmark Coverage for CNSide® CSF Assay, Expanding Reimbursement to ~75 Million Covered Lives [Yahoo! Finance]
3/31
05:15 pm
pstv
Plus Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Low
Report
Plus Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
4/9
08:01 am
pstv
Form 8-K PLUS THERAPEUTICS, INC. For: Apr 08
High
Report
Form 8-K PLUS THERAPEUTICS, INC. For: Apr 08
4/8
07:30 am
pstv
Form 8-K PLUS THERAPEUTICS, INC. For: Apr 08
Medium
Report
Form 8-K PLUS THERAPEUTICS, INC. For: Apr 08
4/2
04:30 pm
pstv
Form 8-K PLUS THERAPEUTICS, INC. For: Apr 01
Medium
Report
Form 8-K PLUS THERAPEUTICS, INC. For: Apr 01
4/1
07:30 am
pstv
Form 4 PLUS THERAPEUTICS, INC. For: Apr 01 Filed by: HEDRICK MARC H
Low
Report
Form 4 PLUS THERAPEUTICS, INC. For: Apr 01 Filed by: HEDRICK MARC H
4/1
07:30 am
pstv
Form 4 PLUS THERAPEUTICS, INC. For: Apr 01 Filed by: Sims Andrew John Hugh MacIntyre
Low
Report
Form 4 PLUS THERAPEUTICS, INC. For: Apr 01 Filed by: Sims Andrew John Hugh MacIntyre
3/31
04:31 pm
pstv
Form DEFA14A PLUS THERAPEUTICS, INC.
Medium
Report
Form DEFA14A PLUS THERAPEUTICS, INC.
3/31
04:25 pm
pstv
Form ARS PLUS THERAPEUTICS, INC. For: Dec 31
Medium
Report
Form ARS PLUS THERAPEUTICS, INC. For: Dec 31
3/31
04:20 pm
pstv
Form DEF 14A PLUS THERAPEUTICS, INC. For: May 14
Low
Report
Form DEF 14A PLUS THERAPEUTICS, INC. For: May 14
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
8/15
Q2/2019 6/30/2019 EPS -5.120 ZacksConsensus N/A ActVsEst N/A - N/A
272.2%
3/30 Form 8-K PLUS THERAPEUTICS, INC. For: Mar 29 57.6%
8/26 Form SC 13G PLUS THERAPEUTICS, INC. Filed by: Sassicaia Capital Advisers LLC 44.6%
11/14 Plus Therapeutics Reports Third Quarter 2019 Financial and Business Results 17.8%
10/15 Form 8-K PLUS THERAPEUTICS, INC. For: Oct 09 10.0%
4/6 Plus Therapeutics Donates Personal Protective Equipment to Scripps Health to Confront COVID-19 Pandemic 9.0%
12/9 Plus Therapeutics to Present at Biotech Showcase 2020 7.4%
9/26 Plus Therapeutics, Inc. Announces Closing of $15 Million Underwritten Public Offering 6.1%
1/6 Plus Therapeutics Shareholder Update: Transition Achieved in 2019; Poised for Expansion in 2020 5.0%
11/4 Plus Therapeutics To Report Fiscal 2019 Third Quarter Financial Results and Corporate Update on November 14, 2019 4.4%
3/30 Form 8-K PLUS THERAPEUTICS, INC. For: Mar 29 57.6%
8/26 Form SC 13G PLUS THERAPEUTICS, INC. Filed by: Sassicaia Capital Advisers LLC 44.6%
11/14 Plus Therapeutics Reports Third Quarter 2019 Financial and Business Results 17.8%
10/15 Form 8-K PLUS THERAPEUTICS, INC. For: Oct 09 10.0%
4/6 Plus Therapeutics Donates Personal Protective Equipment to Scripps Health to Confront COVID-19 Pandemic 9.0%
12/9 Plus Therapeutics to Present at Biotech Showcase 2020 7.4%
9/26 Plus Therapeutics, Inc. Announces Closing of $15 Million Underwritten Public Offering 6.1%
1/6 Plus Therapeutics Shareholder Update: Transition Achieved in 2019; Poised for Expansion in 2020 5.0%
11/4 Plus Therapeutics To Report Fiscal 2019 Third Quarter Financial Results and Corporate Update on November 14, 2019 4.4%
TOP News Decliners
3/12
Form 8-K PLUS THERAPEUTICS, INC. For: Mar 09
-23.6%
8/2 Form 8-K CYTORI THERAPEUTICS, For: Aug 01 -21.6%
3/30 Form 10-K PLUS THERAPEUTICS, INC. For: Dec 31 -20.0%
8/14 Form NT 10-Q PLUS THERAPEUTICS, INC. For: Jun 30 -19.7%
8/21 Plus Therapeutics: Prepare For The Imminent Dilution [Seeking Alpha] -18.5%
7/29 Plus Therapeutics, Inc. Announces Nasdaq Ticker Symbol Changes and Reverse Stock Split -15.0%
9/16 Form S-1/A PLUS THERAPEUTICS, INC. -14.5%
4/1 Plus Therapeutics Announces Dr. Gregory Stein as Head of Clinical Development -13.3%
9/24 Form 424B4 PLUS THERAPEUTICS, INC. -13.2%
8/9 Form 8-K PLUS THERAPEUTICS, INC. For: Aug 09 -12.5%
8/2 Form 8-K CYTORI THERAPEUTICS, For: Aug 01 -21.6%
3/30 Form 10-K PLUS THERAPEUTICS, INC. For: Dec 31 -20.0%
8/14 Form NT 10-Q PLUS THERAPEUTICS, INC. For: Jun 30 -19.7%
8/21 Plus Therapeutics: Prepare For The Imminent Dilution [Seeking Alpha] -18.5%
7/29 Plus Therapeutics, Inc. Announces Nasdaq Ticker Symbol Changes and Reverse Stock Split -15.0%
9/16 Form S-1/A PLUS THERAPEUTICS, INC. -14.5%
4/1 Plus Therapeutics Announces Dr. Gregory Stein as Head of Clinical Development -13.3%
9/24 Form 424B4 PLUS THERAPEUTICS, INC. -13.2%
8/9 Form 8-K PLUS THERAPEUTICS, INC. For: Aug 09 -12.5%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: